biological evaluation of a number of differently substituted 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives are reported. From the inhibition results on a selection of disease-relevant protein kinases [IC50 (μM) DYRK1A = 11; CDK5 = 0.41; GSK-3 = 1.5] we have observed that 3,6-diamino-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile (4) constitutes a potential new and simple lead compound in the
报道了许多不同取代的3,6-二氨基-1 H-吡唑并[3,4- b ]吡啶衍生物的合成和生物学评价。从抑制结果中选择与疾病相关的蛋白激酶[IC 50(μM)DYRK1A = 11;CDK5 = 0.41;GSK-3 = 1.5]我们已经观察到3,6-二氨基-4-苯基-1 H-吡唑并[3,4- b ]吡啶-5-甲腈(4)构成了潜在的新颖且简单的先导化合物用于治疗阿尔茨海默氏病的药物。
Studies on the acetylation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile derivatives
Abstractmagnified image The acetylation reaction of the differently substituted 3,6‐diamino‐1H‐pyrazolo[3,4‐b]pyridine‐5‐carbonitrile derivatives 1, 2, 3, 4, 5, 6 is reported. The structure of the resulting acetamides has been investigated and confirmed by analytical, spectroscopic, and chemical transformations. From these studies, we conclude that, in general, under mild conditions, and using acetic anhydride, when free, the N(1)H moiety is a more reactive center respect to the C(3)NH2 and C(6)NH2 groups. This trend is reversed when no steric hindrance due to presence of a phenyl group at C4 drives the preferred acetylation to C(3)NH2, as it is evident by comparing the observed results from precursor 1 with 3. When N1 is blocked, the (C3)NH2 group undergoes preferential acetylation over the (C6)NH2 site, which only has been mono (or diacetylated) at reflux. Computational analyses based on DFT studies have been extensively used to explain the observed reactivities. J. Heterocyclic Chem., (2010).
EL-MOBAYED, MEDHAT;ESSAWY, ABDEL-NABY;EL-BAHNASAWI, ADEL;AMER, ATEF MOHAM+, GAZZ. CHIM. ITAL., 121,(1991) N, C. 209-212